{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T14:14:35Z","timestamp":1779718475486,"version":"3.53.1"},"reference-count":27,"publisher":"Institute of Biochemistry","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BIOMED KHIM"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>The blood serum antioxidant status and the blood plasma metabolomic profile have been analyzed in Parkinson's disease (PD) patients, both pharmacologically naive and taking levodopa (treatment duration 7.4\u00b15.4 years) at low (&lt; 300 mg\/day) and high (&gt; 300 mg\/day) doses. High-dose levodopa therapy caused changes in both the antioxidant status and metabolome of patients. High-dose levodopa treatment also activated lipid peroxidation, manifested by an increase in the level of lipid hydroperoxides. High-resolution mass spectrometry revealed accumulation of levodopa and dopamine metabolic products in the metabolome, particularly the neurotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), and associated changes in related metabolic pathways. Low-dose levodopa treatment did not cause significant changes in the antioxidant status and metabolome of patients, thus suggesting that maintaining a low-dose regimen as long as possible could potentially reduce neurotoxic metabolite accumulation and also maintain normal antioxidant functions in PD patients.<\/jats:p>","DOI":"10.18097\/pbmcr1642","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:31:56Z","timestamp":1779715916000},"page":"141-151","source":"Crossref","is-referenced-by-count":0,"title":["The effect of levodopa on the blood antioxidant system and metabolome in patients with Parkinson's disease"],"prefix":"10.18097","volume":"72","author":[{"given":"D.A.","family":"Abaimov","sequence":"first","affiliation":[{"name":"Russian Center for Neurology and Neurosciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.N.","family":"Fedorova","sequence":"additional","affiliation":[{"name":"Russian Center for Neurology and Neurosciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Shabalina","sequence":"additional","affiliation":[{"name":"Russian Center for Neurology and Neurosciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Silantyev","sequence":"additional","affiliation":[{"name":"Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.N.","family":"Konanov","sequence":"additional","affiliation":[{"name":"Scientific Research Institute of Systems Biology and Medicine, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.Yu.","family":"Fedotova","sequence":"additional","affiliation":[{"name":"Russian Center for Neurology and Neurosciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.V.","family":"Poleshchuk","sequence":"additional","affiliation":[{"name":"Russian Center for Neurology and Neurosciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.N.","family":"Andreev","sequence":"additional","affiliation":[{"name":"Russian Center for Neurology and Neurosciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.V.","family":"Trifonova","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Maslov","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.E.","family":"Balashova","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Sychev","sequence":"additional","affiliation":[{"name":"The World-class Center for Genomic Research \u201cCenter for Predictive Genetics, Pharmacogenetics and Personalized Therapy\u201d of the Academician B.V. Petrovsky, Russian Scientific Center of Surgery, Moscow, Russia; Russian Medical Academy of Continuing Professional Education, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Illarioshkin","sequence":"additional","affiliation":[{"name":"Russian Center for Neurology and Neurosciences, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Lokhov","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7443","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Whitfield A.C., Moore B.T., Daniels R.N. (2014) Classics in chemical neuroscience: levodopa. ACS Chem. Neurosci., 5(12), 1192\u20131197.","DOI":"10.1021\/cn5001759"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Mena M.A., Casarejos M.J., Solano R.M., de Y\u00e9benes J.G. (2009) Half a century of L-DOPA. Curr. Top. Med. Chem., 9(10), 880\u2013893.","DOI":"10.2174\/156802609789378263"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Chagraoui A., Boulain M., Juvin L., Anouar Y., Barri\u00e8re G., de Deurwaerd\u00e8re P. (2020) L-DOPA in Parkinson\u2019s disease: looking at the \u201cfalse\u201d neurotransmitters and their meaning. Int. J. Mol. Sci., 21(1), 294.","DOI":"10.3390\/ijms21010294"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"M\u00fcller T. (2013) Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson\u2019s disease. Expert Rev. Neurother., 13(6), 707\u2013718.","DOI":"10.1586\/ern.13.50"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Olanow C.W. (2015) Levodopa: effect on cell death and the natural history of Parkinson's disease. Mov. Disord., 30(1), 37\u201344.","DOI":"10.1002\/mds.26119"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Paul R., Borah A. (2016) L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: elephant in the room. Biochim. Biophys. Acta, 1860(9), 1989\u20131997.","DOI":"10.1016\/j.bbagen.2016.06.018"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Melamed E., Offen D., Shirvan A., Ziv I. (2000) Levodopa \u2014 an exotoxin or a therapeutic drug? J. Neurol., 247(Suppl 2), 135\u2013139.","DOI":"10.1007\/pl00022914"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Jenner P. (2015) Treatment of the later stages of Parkinson\u2019s disease \u2014 pharmacological approaches now and in the future. Transl. Neurodegener., 4, 3.","DOI":"10.1186\/2047-9158-4-3"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"G\u00f6tz M.E., Double K., Gerlach M., Youdim M.B.H., Riederer P. (2004) The relevance of iron in the pathogenesis of Parkinson's disease. Ann. NY Acad. Sci., 1012, 193\u2013208.","DOI":"10.1196\/annals.1306.017"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Serra J.A., Dom\u00ednguez R.O., de Lustig E.S., Guareschi E.M., Famulari A.L., Bartolom\u00e9 E.L., Marschoff E.R. (2001) Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J. Neural Transm. (Vienna), 108(10), 1135\u20131148.","DOI":"10.1007\/s007020170003"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Duran R., Barrero F.J., Morales B., Luna J.D., Ramirez M., Vives F. (2011) Oxidative stress and aminopeptidases in Parkinson\u2019s disease patients with and without treatment. Neurodegener. Dis., 8(3), 109\u2013116.","DOI":"10.1159\/000315404"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Gonzalez-Covarrubias V., Mart\u00ednez-Mart\u00ednez E., del Bosque-Plata L. (2022) The potential of metabolomics in biomedical applications. Metabolites, 12(2), 194.","DOI":"10.3390\/metabo12020194"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Shao Y., Li T., Liu Z., Wang X., Xu X., Li S., Xu G., Le W. (2021) Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol. Neurodegener., 16, 4.","DOI":"10.1186\/s13024-021-00425-8"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Branco R.C., Ellsworth W., Niedzwiecki M.M., Butkovich L.M., Walker D.I., Huddleston D.E., Jones D.P., Miller G.W. (2018) Levodopa and dopamine dynamics in Parkinson\u2019s disease metabolomics. BioRxiv, 306266.","DOI":"10.1101\/306266"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Rodriguez-Violante M., Cervantes-Arriaga A. (2014) The movement disorder society-unified Parkinson\u2019s disease rating scale: clinical and research uses. Archivos de Neurociencias, 19(3), 157\u2013163.","DOI":"10.31157\/an.v19i3.50"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Vladimirov Y.A. (1996) Studies of the antioxidant activity by measuring chemiluminescence kinetics. In: Proceedings of the International Symposium on Natural Antioxidants: Molecular Mechanisms and Health Effects (Packer L., Traber M.G., Xin W., eds.), AOCS Press, Champaign, Il., pp. 125\u2013144.","DOI":"10.1201\/9781439832059.ch14"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Fedorova T.N. (2003) Chemiluminescent analysis used for the comparative assessment of the antioxidant activity of pharmacological compounds. Eksperimentalnaya i Klinicheskaya Farmakologiya, 66(5), 56\u201358.","DOI":"10.30906\/0869-2092-2003-66-5-56-58"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Fedorova T.N., Devyatov A.A., Berezhnoi D.S., Stvolinskii S.L., Morozova M.P., Gavrilova S.A., Tutelyan V.A. (2018) Oxidative status in different areas of the cerebral cortex of Wistar rats during focal ischemia and its modulation with carnosine. Bull. Exp. Biol. Med., 165(6), 746\u2013750.","DOI":"10.1007\/s10517-018-4256-x"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Lokhov P.G., Balashova E.E., Voskresenskaya A.A., Trifonova O.P., Maslov D.L., Archakov A.I. (2016) Mass spectrometric signatures of the blood plasma metabolome for disease diagnostics. Biomed. Rep., 4(1), 122\u2013126.","DOI":"10.3892\/br.2015.548"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Lokhov P.G., Dashtiev M.I., Moshkovskii S.A., Archakov A.I. (2010) Metabolite profiling of blood plasma of patients with prostate cancer. Metabolomics, 6(1), 156\u2013163.","DOI":"10.1007\/s11306-009-0187-x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Wishart D.S., Tzur D., Knox C., Eisner R., Guo A.C., Young N., Cheng D., Jewell K., Arndt D., Sawhney S., Fung C., Nikolai L., Lewis M., Coutouly M.A., Forsythe I., Tang P., Shrivastava S., Jeroncic K., Stothard P., Amegbey G., Block D., Hau D.D., Wagner J., Miniaci J., Clements M., Gebremedhin M., Guo N., Zhang Y., Duggan G.E., Macinnis G.D., Weljie A.M., Dowlatabadi R., Bamforth F., Clive D., Greiner R., Li L., Marrie T., Sykes B.D., Vogel H.J., Querengesser L. (2007) HMDB: the Human Metabolome Database. Nucleic Acids Res., 35(Database issue), D521\u2013D526.","DOI":"10.1093\/nar\/gkl923"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Nyangale E.P., Mottram D.S., Gibson G.R. (2012) Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J. Proteome Res., 11(12), 5573\u20135585.","DOI":"10.1021\/pr300637d"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Heetun Z.S., Quigley E.M.M. (2012) Gastroparesis and Parkinson's disease: a systematic review. Parkinsonism Relat. Disord., 18(5), 433\u2013440.","DOI":"10.1016\/j.parkreldis.2011.12.004"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Kori M., Ayd\u0131n B., Unal S., Arga K.Y., Kazan D. (2016) Metabolic biomarkers and neurodegeneration: a pathway enrichment analysis of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. OMICS, 20(11), 645\u2013661.","DOI":"10.1089\/omi.2016.0106"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Contin M., Martinelli P. (2010) Pharmacokinetics of levodopa. J. Neurol., 257(Suppl 2), S253\u2013S261.","DOI":"10.1007\/s00415-010-5728-8"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Goldstein D.S. (2021) The catecholaldehyde hypothesis for the pathogenesis of catecholaminergic neurodegeneration: what we know and what we do not know. Int. J. Mol. Sci., 22(11), 5999.","DOI":"10.3390\/ijms22115999"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Marchitti S.A., Deitrich R.A., Vasiliou V. (2007) Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev., 59(2), 125\u2013150.","DOI":"10.1124\/pr.59.2.1"}],"container-title":["Biomeditsinskaya Khimiya"],"original-title":[],"language":"ru","deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:32:04Z","timestamp":1779715924000},"score":1,"resource":{"primary":{"URL":"http:\/\/pbmc.ibmc.msk.ru\/en\/article-en\/PBMC-2026-72-2-141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]},"published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.18097\/pbmcr1642","relation":{},"ISSN":["2310-6905","2310-6972"],"issn-type":[{"value":"2310-6905","type":"electronic"},{"value":"2310-6972","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}